These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 14521486

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.
    Cochrane Database Syst Rev; 2017 Aug 15; 8(8):CD007476. PubMed ID: 28809446
    [Abstract] [Full Text] [Related]

  • 3. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; (8):CD004839. PubMed ID: 23966105
    [Abstract] [Full Text] [Related]

  • 4. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 5. [Iron chelation in 1998].
    de Montalembert M.
    Transfus Clin Biol; 1998 Oct 18; 5(5):353-6. PubMed ID: 9836396
    [Abstract] [Full Text] [Related]

  • 6. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 7. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
    Kontoghiorghes GJ, Neocleous K, Kolnagou A.
    Drug Saf; 2003 Apr 10; 26(8):553-84. PubMed ID: 12825969
    [Abstract] [Full Text] [Related]

  • 8. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F.
    Eur J Haematol; 2001 Jul 10; 67(1):30-4. PubMed ID: 11553264
    [Abstract] [Full Text] [Related]

  • 9. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793
    [Abstract] [Full Text] [Related]

  • 10. Oral iron chelation therapy for thalassaemia: an uncertain scene.
    Pippard MJ, Weatherall DJ.
    Br J Haematol; 2000 Oct 21; 111(1):2-5. PubMed ID: 11091177
    [No Abstract] [Full Text] [Related]

  • 11. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ, Kolnagou A.
    Haematologica; 2006 Jun 21; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [Abstract] [Full Text] [Related]

  • 12. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A.
    Transfus Sci; 2000 Dec 21; 23(3):211-23. PubMed ID: 11099897
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Dec 21; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 14. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 21; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 15. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
    Kontoghiorghes GJ.
    Expert Opin Emerg Drugs; 2006 Mar 21; 11(1):1-5. PubMed ID: 16503822
    [Abstract] [Full Text] [Related]

  • 16. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S.
    Cochrane Database Syst Rev; 2005 Oct 19; (4):CD004450. PubMed ID: 16235363
    [Abstract] [Full Text] [Related]

  • 17. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.
    Ann Hematol; 2008 Jul 19; 87(7):545-50. PubMed ID: 18351337
    [Abstract] [Full Text] [Related]

  • 18. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007476. PubMed ID: 22336831
    [Abstract] [Full Text] [Related]

  • 19. Combined therapy with deferiprone and desferrioxamine.
    Wonke B, Wright C, Hoffbrand AV.
    Br J Haematol; 1998 Nov 15; 103(2):361-4. PubMed ID: 9827905
    [Abstract] [Full Text] [Related]

  • 20. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Res (Stuttg); 2017 Jul 15; 67(7):404-411. PubMed ID: 28320041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.